×
About 63,045 results

Germline Variants Identified in Patients with Early-onset Renal Cell Carcinoma Referred for Germline Genetic Testing
https://pubmed.ncbi.nlm.nih.gov/34654685/
European Urology Oncology; Truong H

Oct 12th, 2021 - Despite guidelines recommending genetic counseling for patients with early-onset renal cell carcinoma (RCC), studies interrogating the spectrum of germline mutations and clinical associations in patients with early-onset RCC are lacking.

Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report
https://www.medrxiv.org/content/10.1101/2021.10.10.21264827v1.full.pdf
Medrxiv Atmar RL, .

Oct 13th, 2021 - Background: While Coronavirus disease 2019 (Covid-19) vaccines are highly effective, breakthrough infections are occurring. Booster vaccinations have recently received emergency use authorization (EUA) for certain populations but are restricted to homologous mRNA vaccines. We evaluated homologous and heterologous booster vaccination in persons who had received an EUA Covid-19 vaccine regimen.

The V2475F CPVT1 mutation yields distinct RyR2 channel populations that differ in their...
https://doi.org/10.1113/JP281707
The Journal of Physiology; Wilson AD, Hu J et. al.

Oct 23rd, 2021 - RyR2 mutations can cause type-1 catecholaminergic polymorphic ventricular tachycardia (CPVT1), a lethal, autosomal-dominant arrhythmic disease. However, the changes in RyR2 ion-channel function that result from the many different patient mutations are rarely investigated in detail and often only recombinant RyR2, homozygous for the mutation, are studied. As CPVT1 is a heterozygous disease and t...

SUFU haploinsufficiency causes a recognisable neurodevelopmental phenotype at the mild ...
https://doi.org/10.1136/jmedgenet-2021-108114
Journal of Medical Genetics; Serpieri V, D'Abrusco F et. al.

Oct 23rd, 2021 - Joubert syndrome (JS) is a recessively inherited ciliopathy characterised by congenital ocular motor apraxia (COMA), developmental delay (DD), intellectual disability, ataxia, multiorgan involvement, and a unique cerebellar and brainstem malformation. Over 40 JS-associated genes are known with a diagnostic yield of 60%-75%.In 2018, we reported homozygous hypomorphic missense variants of the SUF...

Proteomic analysis of the host-pathogen interface in experimental cholera.
https://doi.org/10.1038/s41589-021-00894-4 10.1038/nmeth.1714 10.1016/j.cell.2014.04.028 10.1038/s41467-019-12672-x 10.1128/mr.47.4.510-550.1983 10.1016/S0140-6736(17)30559-7 10.3390/toxins2030310 10.1038/1831533a0 10.1128/mBio.00047-10 10.1084/jem.168.4.1487 10.1016/j.chom.2011.07.007 10.1016/j.chom.2013.11.001 10.1371/journal.pgen.1004782 10.1371/journal.ppat.1003800 10.1128/IAI.00585-08 10.1073/pnas.1403683111 10.1038/nchembio.2025 10.1056/NEJMoa1012928 10.1038/s41586-019-1453-3 10.1371/journal.pone.0007352 10.1021/pr201135e 10.1038/nmeth745 10.3389/fmicb.2019.02057 10.1002/pro.2815 10.1046/j.1365-2958.2001.02683.x 10.1016/0378-1119(95)00054-A 10.1073/pnas.1712837114 10.1165/rcmb.2005-0462OC 10.1165/ajrcmb.24.4.3504 10.1016/j.jsb.2016.06.019 10.1128/IAI.72.2.709-716.2004 10.3389/fimmu.2012.00354 10.3390/ijms19041045 10.1007/s12275-018-7545-1 10.1016/j.redox.2020.101524 10.1016/S1534-5807(03)00090-X 10.1126/science.283.5409.1914 10.1038/cmi.2014.105 10.1038/nchembio.1525 10.1093/femsre/fuv008 10.1016/j.cell.2014.08.006 10.1172/JCI117323 10.3389/fcimb.2020.00229 10.1038/nmicrobiol.2016.125 10.1073/pnas.1431769100 10.1038/nsmb.3053 10.1038/nbt.2839 10.1371/journal.ppat.1009290 10.21769/BioProtoc.1455 10.1038/s41587-019-0209-9 10.1038/nmeth.3869 10.1371/journal.pone.0067019 10.1093/nar/30.1.207
Nature Chemical Biology; Zoued A, Zhang H et. al.

Oct 23rd, 2021 - The microbial cell surface is a site of critical microbe-host interactions that often control infection outcomes. Defining the set of host proteins present at this interface has been challenging. Here we used a surface-biotinylation approach coupled to quantitative mass spectrometry to identify and quantify both bacterial and host proteins present on the surface of diarrheal fluid-derived Vibri...

Efficacy and safety of Wilms' tumor 1 helper peptide OCV-501 in elderly patients with a...
https://doi.org/10.1007/s00262-021-03074-4 10.1002/hon.2046 10.2217/fon-2017-0459 10.1158/1078-0432.CCR-17-3016 10.1016/0092-8674(90)90601-a 10.1038/343774a0 10.1073/pnas.0405884101 10.1097/CJI.0b013e3181f3cc5c 10.3389/fimmu.2015.00036 10.1186/1479-5876-8-5 10.3324/haematol.2010.031674 10.4049/jimmunol.165.11.6047 10.1038/nature01441 10.3390/vaccines3030490 10.1002/cncr.24988 10.1007/s00262-017-1981-3 10.1200/JCO.2008.17.0472 10.17925/EOH.2008.02.1.71 10.1200/JCO.2009.23.2652 10.1200/JCO.2003.04.036 10.21037/sci.2016.11.08 10.3324/haematol.2010.031674 10.1007/s00262-010-0929-7 10.1182/bloodadvances.2017014175 10.3389/fphar.2019.01184 10.3389/fimmu.2019.00467 10.1038/sj.leu.2403186 10.1159/000481353 10.1002/ijc.30182 10.1007/s00262-018-2274-1 10.1016/j.phrs.2017.07.006 10.1016/j.canlet.2019.05.017 10.3389/fimmu.2020.00784 10.3389/fonc.2020.00262 10.1016/j.imlet.2019.03.006 10.3389/fonc.2018.00213 10.1016/j.bbmt.2018.06.016 10.2217/fon.15.326 10.1016/j.clml.2019.04.004 10.1038/s41409-019-0493-5
Cancer Immunology, Immunotherapy : CII; Kiguchi T, Yamaguchi M et. al.

Oct 23rd, 2021 - Complete remission (CR) of acute myeloid leukemia (AML) in elderly patients has a short duration, and there is no suitable post-remission therapy. We explored the role of the Wilms' tumor 1 helper peptide OCV-501 to prevent recurrence after remission. This placebo-controlled phase 2 study was designed to evaluate accurately the efficacy and immunogenicity of OCV-501 in elderly AML patients. Eld...

Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT04344795

Oct 22nd, 2021 - This is a first-in-human Phase 1a/1b, multicenter, open-label, dose-escalation, dose and schedule optimization, and expansion study of TPST-1495 as a single agent and in combination with pembrolizumab to determine its MTD, safety, tolerability, pharmacokinetics (PD), pharmacodynamics (PK) and preliminary anti-tumor activity in subjects with advanced solid tumors. Subjects with all histologic ty...

Maintenance Ipilimumab + Nivolumab Post Induction Chemotherapy + SBRT for First Line Treatment Stage IV Pancreatic Cancer
https://clinicaltrials.gov/ct2/show/NCT05088889

Oct 22nd, 2021 - This is a single arm, single institution study, which aims to evaluate the efficacy and safety of combination therapy with radiosurgery nivolumab and ipilimumab as a maintenance regimen following first line induction chemotherapy in patients with metastatic pancreatic cancer. Chemotherapy will be administrated for a minimum of 4 cycles. Patients who have not progressed on chemotherapy will rece...

Yang Yin Fu Zheng Jie Du Therapy in HBV Related Hepatocellular Carcinoma Induced Anemia (YYFZJDTIHBVRHCIA)
https://clinicaltrials.gov/ct2/show/NCT05088733

Oct 22nd, 2021 - Clinical research of Yang Yin Fu Zheng Jie Du therapy in HBV related hepatocellular carcinoma induced anemia. The purpose of this study is to observe the efficacy of routine medical care combined with Yang Yin Fu Zheng Jie Du therapy for patients belong to HBV-HCC induced anemia.

Breast Cancer and Kinesiophia and Physical Activity
https://clinicaltrials.gov/ct2/show/NCT05090098

Oct 22nd, 2021 - Breast cancer is the most common type of cancer in women worldwide. A significant number of breast cancer survivors develop many complications. Breast cancer and survivors may develop a fear of physical activity avoidance and movement, called kinesiophobia, due to upper extremity pain, numbness, restricted arm/shoulder range of motion, and risk of lymphedema. Therefore, in the present study, it...

Tissue Collection for Studies of Lymph Cancer
https://clinicaltrials.gov/ct2/show/NCT01676805

Oct 22nd, 2021 - Background: An estimated 79,190 people living in the United States will be diagnosed with lymphoma in 2012, including 9,060 cases of HL, 70,130 cases of non-Hodgkin s lymphoma (NHL) and multiple cases of adult T-cell leukemia/lymphoma. Laboratory investigations conducted in the Lymphoid Malignancies Branch, including analysis of cellular, molecular, genetic and genomic biology are attempting to...

Efficacy and Safety of Systemic Treatments of Bone Metastases From Kidney Cancer in Patients Treated With Targeted Therapies
https://clinicaltrials.gov/ct2/show/NCT03408652

Oct 22nd, 2021 - Multicenter, randomized, open-label, 2-arm, parallel-group, phase III study whose goal is to assess the efficacy and safety profile of bone-targeted treatments (Arm A: denosumab or zoledronic acid) versus the control arm (Arm B: no specific treatment) in patients with bone metastases under targeted therapy for Metastatic Renal Cell Carcinoma.

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab an...
https://clinicaltrials.gov/ct2/show/NCT04736706

Oct 22nd, 2021 - The goal of this study is to evaluate the efficacy and safety of pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib as first-line treatment in participants with advanced clear cell renal cell carcinoma (ccRCC). The primary hypotheses are (1) pembrolizumab plus belzutifan plus lenvatinib is superior to pembrolizumab plu...

Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).
https://clinicaltrials.gov/ct2/show/NCT04566133

Oct 22nd, 2021 - Background: Among the new cases of bile tract carcinoma (BTC) that are diagnosed every year in the United States, there are approximately 6,500 cases of gallbladder carcinoma, 3,000 cases of extrahepatic cholangiocarcinoma, and 3,000 cases of intrahepatic cholangiocarcinoma. Current treatment options for patients with cholangiocarcinoma are limited and take no account of the known biological an...

A Study of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018)
https://clinicaltrials.gov/ct2/show/NCT04846920

Oct 22nd, 2021 - The goal of this study is to evaluate the safety, tolerability and pharmacokinetics of escalating doses of belzutifan as second line positive (2L+) treatment in participants with advanced clear cell renal cell carcinoma (ccRCC).

Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or ...
https://clinicaltrials.gov/ct2/show/NCT03867084

Oct 22nd, 2021 - This study will evaluate the safety and efficacy of pembrolizumab (MK-3475) versus placebo as adjuvant therapy in participants with hepatocellular carcinoma (HCC) and complete radiological response after surgical resection or local ablation. The primary hypotheses of this study are that adjuvant pembrolizumab is superior to placebo with respect to: 1) recurrence-free survival (RFS) as assessed ...

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer
https://clinicaltrials.gov/ct2/show/NCT04092270

Oct 22nd, 2021 - PRIMARY OBJECTIVE: I. To determine the safety and tolerability of peposertib (M3814) in combination with pegylated liposomal doxorubicin hydrochloride (PLD) and determine the recommended phase 2 dose (RP2D) of the combination in women with recurrent ovarian cancer. SECONDARY OBJECTIVES: I. To observe and record anti-tumor activity. II. To evaluate the pharmacokinetics of M3814 when given in com...

Natural Killer Cells and Bortezomib to Treat Cancer
https://clinicaltrials.gov/ct2/show/NCT00720785

Oct 22nd, 2021 - Natural killer (NK) cells are innate immune lymphocytes that are identified by the expression of the CD56 surface antigen and the lack of CD3. Unlike antigen specific T cells, NK cells do not require the presence of a specific tumor antigen for the recognition and killing of cancer cells. Our in vitro studies have demonstrated that pretreatment of malignant cells with bortezomib significantly e...

Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budig...
https://clinicaltrials.gov/ct2/show/NCT04807972

Oct 22nd, 2021 - Metastatic Pancreatic Cancer Disease is one of the most aggressive and deadliest forms of cancer with very poor survival. This study will evaluate adverse events and change in disease activity in participants 18 to 75 years of age with a body weight greater than or equal to 35 kg with Metastatic Pancreatic Cancer Disease treated with Intravenous (IV) infusion of modified FOLFIRINOX (mFFX) combi...

Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT04933539

Oct 22nd, 2021 - Background: Smoldering multiple myeloma (SMM) is a precursor condition to MM defined by the clinical parameters of M-protein >=3.0 g/dL or bone marrow plasma cells >=10%, and absence of end organ disease. Patients with high-risk SMM have a risk of progression to MM of 72-75% in 5 years with median time to progression of <2 years. The current standard of care for SMM is close follow-up without t...